Clinical trials: multiple sclerosis
Multiple Sclerosis
Accurate Diagnosis of Multiple Sclerosis Using PET/MR
Multiple sclerosis (MS) is an immune-mediated chronic inflammatory demyelinating disease of the central nervous system. Its main feature is progressive demyelination, which ultimately leads to axon damage and neuron loss.
- Trial name
- NCT04521439
- Testing
- 18F-florbetapir PET+MRSI
- Where
- China
- Volunteers
- 49 people, healthy volunteers welcome
- Sponsor
- Ruijin Hospital
Multiple Sclerosis Relapse, Surgery
Postoperative Relapses in MS Patients
The aim of the study is to record any relapses during one year postoperatively in patients and parturients diagnosed with MS who received general or regional anesthesia
- Conditions
- Multiple Sclerosis Relapse, Surgery, Anesthesia
- Trial name
- NCT04237675
- Testing
- surgery and anesthesia
- Where
- 2 sites in Greece
- Volunteers
- 300 people
- Sponsor
- University of Athens
Multiple Sclerosis
Telerehabilitation Based Motor Imagery and Action Observation Training in Multiple Sclerosis
This study aims to investigate the effects of the treatment combination consisting of motor imagery and action observation therapy on balance, functional mobility, lower extremity muscle strength, fatigue and quality of life.
- Trial name
- NCT06295601
- Testing
- Traditional rehabilitation, Action observation therapy and motor imagery
- Where
- Turkey (Türkiye)
- Volunteers
- 29 people, healthy volunteers welcome
- Sponsor
- Inonu University
Multiple Sclerosis, Relapsing-Remitting
Assessment of Repeat Ascending Doses of GSK2018682 in Healthy Volunteers
The study will evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of repeat ascending doses of GSK2018682.
- Trial name
- P1A114347 (NCT01431937)
- Testing
- GSK2018682
- Where
- 3 sites in Australia
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis
POPART'MUS: Prevention of Post Partum Relapses With Progestin and Estradiol in Multiple Sclerosis
Multiple sclerosis (MS) affects 1 in 1000 people in western countries, mainly women in their childbearing years. It is an autoimmune disease of the central nervous system (CNS), which results in a chronic focal inflammatory…
- Trial name
- NCT00127075
- Testing
- nomegestrol acetate, estradiol
- Where
- France
- Volunteers
- 300 people
- Sponsor
- Hospices Civils de Lyon
Multiple Sclerosis
Excitotoxicity Markers and the Clinical-radiological Progression After a Demyelinating Event: a Prospective Pilot Study
Multiple sclerosis (MS) is an inflammatory disease of the central nervous system, beginning most often in subjects aged 20-40 years.
- Trial name
- EXCEED (NCT02523703)
- Testing
- glutamate and aspartate
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- University Hospital, Caen
Multiple Sclerosis, Acute Optic Neuritis
Pharmacokinetics, Safety and Tolerability of Single Doses of BIIB033 (Opicinumab) Produced by 2 Manufacturing Processes
The primary objective of the study is to characterize the pharmacokinetics (PK) of BIIB033-B and to compare the PK profile with that of BIIB033-A in healthy volunteers.
- Trial name
- NCT02833142
- Testing
- BIIB033 (opicinumab)
- Where
- United States
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- Biogen
Multiple Sclerosis
Demographics, Clinical and Paraclinical Characteristics of Multiple Sclerosis in Egypt
The primary study aim is to depict the demographics, clinical and para clinical features of patients attending five tertiary referral multiple sclerosis (MS) centers in Egypt.
- Trial name
- NCT02970370
- Testing
- no intervention
- Volunteers
- 2,752 people
- Sponsor
- Cairo University
Multiple Sclerosis
[18F]PBR111 and Microglial Activation in Multiple Sclerosis
This is a study aimed to characterize [18F]PBR111 as an in vivo marker of microglial activation in Multiple Sclerosis. Regional binding of [18F]PBR111 will be quantified with PET in the brain of up to 24 patients with multiple…
- Trial name
- NCT01428505
- Testing
- [18F]PBR111
- Where
- United Kingdom
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Multiple Sclerosis, Constipation
Lubiprostone in Patients With Multiple Sclerosis Associated Constipation
The purpose of the study is to assess how safe and effective the drug Lubiprostone is in people with Multiple Sclerosis (MS)and moderate to severe MS-associated constipation.
- Trial name
- NCT01236534
- Testing
- Lubiprostone
- Where
- United States
- Volunteers
- 21 people
- Sponsor
- University of Rochester
Multiple Sclerosis
Prolonged-release Fampridine as Adjunct Therapy to Active Motor Training in MS Patients
Phase 4, single center, double-blind, placebo-controlled study. Fifty (50) patients with MacDonald criteria (2005) multiple sclerosis will undergo active motor training as per the NeuroGym protocol, consisting of 3 sessions of 1…
- Trial name
- NCT02146534
- Testing
- extended release fampridine
- Where
- Canada
- Volunteers
- 44 people
- Sponsor
- Clinique Neuro-Outaouais
Central Neuropathic Pain, Multiple Sclerosis
Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
The objectives of the study are to evaluate the safety, tolerability, and efficacy of 3 doses of AVP-923 capsules in the treatment of central neuropathic pain in participants with multiple sclerosis.
- Trial name
- PRIME (NCT01324232)
- Testing
- AVP-923-45, AVP-923-30, AVP-923-20
- Where
- 72 sites in United States, Argentina and 3 more
- Volunteers
- 209 people
- Sponsor
- Avanir Pharmaceuticals
Multiple Sclerosis, Gait Disorders, Neurologic
TRAIN-BW: Backward Walking Training in Multiple Sclerosis
Individuals with multiple sclerosis (MS) experience in impairments in mobility and cognition that increase the risk for accidental falls. More than 50% of individuals with MS experience injurious falls within a 6-month period.
- Conditions
- Multiple Sclerosis, Gait Disorders, Neurologic, Accidental Fall
- Trial name
- TRAIN-BW (NCT04091464)
- Testing
- Backward Walking Training, Forward Walking Training
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- Wayne State University
Tuberous Sclerosis Complex
Trial of RAD001 and Neurocognition in Tuberous Sclerosis Complex (TSC)
Tuberous Sclerosis Complex (TSC) is a multi-system disease, usually presenting with seizures, mental retardation and autism, and exhibiting a high variability in clinical findings both among and within families.
- Trial name
- TSC (NCT01289912)
- Testing
- RAD001
- Where
- 2 sites in United States
- Volunteers
- 52 people
- Sponsor
- Mustafa Sahin
Multiple Sclerosis
Costs, Quality of Life and Functional Outcomes in Veterans Treated for Multiple Sclerosis With Beta-Interferon l-B (Betaseron)
The treatment of multiple sclerosis was evolving in light of specific drug therapies to treat the disease, refinements and acceptance of imaging with MRI to diagnose and monitor the disease process, and progress in understanding…
- Trial name
- NCT00439257
- Where
- United States
- Volunteers
- 124 people
- Sponsor
- US Department of Veterans Affairs
Amyotrophic Lateral Sclerosis, Brainstem Stroke
Optimizing BCI-FIT: Brain Computer Interface - Functional Implementation Toolkit
This project adds to non-invasive BCIs for communication for adults with severe speech and physical impairments due to neurodegenerative diseases.
- Conditions
- Amyotrophic Lateral Sclerosis, Brainstem Stroke, Muscular Dystrophies, Parkinson's Disease and Parkinsonism
- Trial name
- BCI-FIT (NCT04468919)
- Testing
- BCI-FIT multi-modal access, BCI-FIT adaptive signal modeling, BCI-FIT active querying
- Where
- United States
- Volunteers
- 55 people, healthy volunteers welcome
- Sponsor
- Oregon Health and Science University
Secondary Progressive Multiple Sclerosis
Mayzent (Siponimod) Onboarding of Secondary Progressive Multiple Sclerosis (SPMS) Patients With MSGo
This study was a retrospective, non-interventional, longitudinal, descriptive study. This study did not have a key underlying hypothesis, rather it was designed to explore the onboarding and adherence of SPMS patients in…
- Trial name
- NCT05826028
- Where
- 2 sites in Australia
- Volunteers
- 368 people
- Sponsor
- Novartis Pharmaceuticals
Multiple Sclerosis
Comprehensive Rehabilitation Programme in People With Multiple Sclerosis: The RECONNECT-MS Study
The goal of this clinical trial is to learn if a comprehensive rehabilitation programme can improve physical function, reduce fatigue, and raise quality of life in adults aged 18-65 with multiple sclerosis (MS).
- Trial name
- RECONNECT-MS (NCT07666958)
- Testing
- Individual Physiotherapy, Group Movement Awareness, Group Psychotherapy
- Where
- Czechia
- Volunteers
- 45 people
- Sponsor
- Charles University, Czech Republic
Multiple Sclerosis, Ambulation Difficulty
Effects of a Home Based Walking Program Using Rhythmic Auditory Stimulation in Patients With Multiple Sclerosis
Rhythmic Auditory Stimulation (RAS) is a music therapy technique that provides rhythmic auditory cues (like a beat) to help improve patients' movements, especially when walking.
- Trial name
- NCT02065284
- Testing
- Rhythmic Auditory Stimulation (RAS)
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- The Cleveland Clinic
Multiple Sclerosis, EDSS 4-7
Efficiency of 4-aminopyridin (Fampyra) on Gait, Vision, Cognition, Fatigue and Micturation in Patients With Multiple Sclerosis
The aim of the study is to assess improvement in visual evoked potential, cognition, fatigue, micturation and walking impairment under 3 months of Fampyra treatment
- Trial name
- NCT01720849
- Testing
- Fampyra
- Where
- Norway
- Volunteers
- 50 people
- Sponsor
- Vestre Viken Hospital Trust
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.